Logos Global Management LP Invests $14.19 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Logos Global Management LP acquired a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,050,000 shares of the company’s stock, valued at approximately $14,186,000. Stoke Therapeutics makes up approximately 1.1% of Logos Global Management LP’s portfolio, making the stock its 23rd largest position. Logos Global Management LP owned approximately 1.99% of Stoke Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. Birchview Capital LP grew its stake in shares of Stoke Therapeutics by 147.1% in the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock valued at $1,105,000 after buying an additional 125,000 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Stoke Therapeutics in the 1st quarter valued at about $1,224,000. BNP Paribas Financial Markets grew its stake in shares of Stoke Therapeutics by 86.2% in the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after buying an additional 6,636 shares during the period. Chase Investment Counsel Corp acquired a new stake in shares of Stoke Therapeutics in the 1st quarter valued at about $279,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Stoke Therapeutics in the 1st quarter valued at about $141,000.

Stoke Therapeutics Stock Down 3.5 %

Shares of NASDAQ STOK opened at $13.27 on Tuesday. Stoke Therapeutics, Inc. has a twelve month low of $3.35 and a twelve month high of $17.58. The stock’s 50 day moving average price is $14.48 and its 200-day moving average price is $13.24. The company has a market capitalization of $691.65 million, a PE ratio of -5.51 and a beta of 0.96.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The firm had revenue of $4.83 million for the quarter, compared to the consensus estimate of $3.33 million. As a group, research analysts expect that Stoke Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $13.75, for a total transaction of $137,500.00. Following the sale, the insider now owns 2,485 shares of the company’s stock, valued at approximately $34,168.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Skorpios Trust sold 1,937,500 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The disclosure for this sale can be found here. 11.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

STOK has been the subject of several research reports. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. Finally, Wedbush reiterated an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research note on Thursday, July 11th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.40.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.